{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-027688","form_type":"8-K","ticker":"EXOZ","cik":"0002010788","company_name":"EXOZYMES INC.","filed_at":"2026-06-08T18:19:49+00:00","discovered_at":"2026-06-08T18:21:00.559011+00:00","generated_at":"2026-06-08T18:21:21.343915+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"eXoZymes prices $5.33M offering of common stock and warrants at $18/unit","bullets":["Sold 592,270 shares and 296,135 warrants as units at $18.00; gross proceeds ~$5.33M.","Warrants exercisable after 1 year at $11.24/share, expire in 5 years; redeemable at $0.01 if stock ≥ $17.98.","Underwriter MDB Capital; over-allotment option for additional 44,420 units (45 days).","Net proceeds to fund NCT development, R&D, and general corporate purposes; close expected June 9, 2026.","Warrant exercise price resets to $0.001 if Company sells shares below $8.99 within 12 months (subject to holding requirement)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-027688","json":"https://secwatch.observer/filing/0001493152-26-027688.json","markdown":"https://secwatch.observer/filing/0001493152-26-027688.md","text":"https://secwatch.observer/filing/0001493152-26-027688.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2010788/000149315226027688/0001493152-26-027688-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2010788/000149315226027688/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T18:21:21.343915+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aa1730d3e76d69b90ac22f8ac7d026d1382b6c80","claim":"EXOZYMES INC. entered into Underwriting Agreement with MDB Capital valued at approximately $5,330,430 (effective 2026-06-05).","evidence_excerpt":"On June 5, 2026, eXoZymes Inc. (the “Company”) entered into (i) an Underwriting Agreement (the “Underwriting Agreement”), dated as of June 5, 2026, with MDB Capital (“MDB”), as the sole underwriter and book runner, pursuant to which the Company agreed to issue and sell, in a firm commitment underwritten offering (the “Offering”) an aggregate of 592,270 shares of common stock (the “Shares”), $0.000001 par value per share (the “Common Stock”), of the Company and 292,135 warrants to purchase up to an aggregate of 292,135 shares of Common Stock (the “Warrants”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2010788/000149315226027688/0001493152-26-027688-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"MDB Capital"},{"label":"Value","value":"approximately $5,330,430"},{"label":"Effective","value":"2026-06-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}